Rhumbline Advisers Vanda Pharmaceuticals Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 90,112 shares of VNDA stock, worth $448,757. This represents 0.0% of its overall portfolio holdings.

Number of Shares
90,112
Previous 99,554 9.48%
Holding current value
$448,757
Previous $562,000 24.91%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$4.61 - $6.34 $43,527 - $59,862
-9,442 Reduced 9.48%
90,112 $422,000
Q2 2024

Aug 01, 2024
BUY
$3.91 - $6.5 $4,809 - $7,995
1,230 Added 1.25%
99,554 $562,000
Q1 2024

May 09, 2024
SELL
$3.47 - $4.61 $5,836 - $7,754
-1,682 Reduced 1.68%
98,324 $404,000
Q4 2023

Feb 08, 2024
SELL
$3.38 - $4.58 $6,540 - $8,862
-1,935 Reduced 1.9%
100,006 $422,000
Q3 2023

Nov 09, 2023
SELL
$4.28 - $6.57 $431,282 - $662,039
-100,767 Reduced 49.71%
101,941 $440,000
Q2 2023

Aug 08, 2023
BUY
$5.9 - $6.95 $53,690 - $63,245
9,100 Added 4.7%
202,708 $1.34 Million
Q1 2023

May 11, 2023
BUY
$6.18 - $7.99 $52,437 - $67,795
8,485 Added 4.58%
193,608 $1.32 Million
Q4 2022

Feb 14, 2023
BUY
$6.87 - $10.96 $65,134 - $103,911
9,481 Added 5.4%
185,123 $1.37 Million
Q3 2022

Nov 10, 2022
BUY
$9.44 - $11.76 $5,796 - $7,220
614 Added 0.35%
175,642 $1.74 Million
Q2 2022

Aug 11, 2022
BUY
$9.31 - $11.84 $89,478 - $113,794
9,611 Added 5.81%
175,028 $1.91 Million
Q1 2022

May 12, 2022
SELL
$10.84 - $16.55 $34,135 - $52,115
-3,149 Reduced 1.87%
165,417 $1.87 Million
Q4 2021

Feb 10, 2022
SELL
$15.69 - $21.14 $43,037 - $57,987
-2,743 Reduced 1.6%
168,566 $2.65 Million
Q3 2021

Nov 12, 2021
SELL
$15.35 - $21.27 $313,370 - $434,227
-20,415 Reduced 10.65%
171,309 $2.94 Million
Q2 2021

Aug 05, 2021
SELL
$15.71 - $21.51 $143,699 - $196,751
-9,147 Reduced 4.55%
191,724 $4.12 Million
Q1 2021

May 06, 2021
SELL
$13.42 - $20.28 $4,146 - $6,266
-309 Reduced 0.15%
200,871 $3.02 Million
Q4 2020

Feb 10, 2021
BUY
$9.77 - $13.81 $174,619 - $246,826
17,873 Added 9.75%
201,180 $2.64 Million
Q3 2020

Nov 12, 2020
SELL
$9.32 - $12.02 $145,140 - $187,187
-15,573 Reduced 7.83%
183,307 $1.77 Million
Q2 2020

Aug 13, 2020
BUY
$9.66 - $12.02 $225,561 - $280,667
23,350 Added 13.3%
198,880 $2.28 Million
Q1 2020

May 06, 2020
BUY
$7.5 - $16.8 $23,722 - $53,138
3,163 Added 1.84%
175,530 $1.82 Million
Q4 2019

Feb 05, 2020
BUY
$12.38 - $17.47 $108,572 - $153,211
8,770 Added 5.36%
172,367 $2.83 Million
Q3 2019

Oct 23, 2019
BUY
$12.27 - $15.79 $61,288 - $78,871
4,995 Added 3.15%
163,597 $2.17 Million
Q2 2019

Aug 14, 2019
BUY
$13.37 - $18.85 $115,690 - $163,109
8,653 Added 5.77%
158,602 $2.24 Million
Q1 2019

May 01, 2019
BUY
$17.59 - $31.05 $14,634 - $25,833
832 Added 0.56%
149,949 $2.76 Million
Q4 2018

Jan 31, 2019
BUY
$18.97 - $31.47 $231,358 - $383,808
12,196 Added 8.91%
149,117 $3.9 Million
Q3 2018

Nov 07, 2018
BUY
$18.25 - $23.0 $1.56 Million - $1.96 Million
85,370 Added 165.6%
136,921 $3.14 Million
Q2 2018

Aug 06, 2018
BUY
$13.95 - $19.15 $130,641 - $179,339
9,365 Added 22.2%
51,551 $982,000
Q1 2018

May 02, 2018
SELL
$14.05 - $20.2 $14,190 - $20,402
-1,010 Reduced 2.34%
42,186 $711,000
Q4 2017

Feb 09, 2018
SELL
$12.85 - $18.1 $104,406 - $147,062
-8,125 Reduced 15.83%
43,196 $657,000
Q3 2017

Nov 06, 2017
BUY
$15.4 - $18.85 $790,343 - $967,400
51,321
51,321 $919,000

Others Institutions Holding VNDA

# of Institutions
161
Shares Held
45.2M
Call Options Held
165K
Put Options Held
33.6K
View Full List

About Vanda Pharmaceuticals Inc.

VNDA Quotes by TradingView
  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $282M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email